Académique Documents
Professionnel Documents
Culture Documents
First Edition
Table of contents Page
A. Foreword…………………………………………………………………….….3
B. Acknowledgments…………………………………………………………….4
C. Glossary………………………………………………………………………...5
D. APPENDICES………………………………………………………….…..…..25
Clinical Trial Application Form…………………………………..……..…… 27
Format for Investigator’s Curriculum Vitae………………………….…..….40
Joint Financial Declaration by Sponsor and Principle Investigator…....…41
Declaration by Principle Investigator…………………………………......…42
Declaration by Co-investigator………………………………………..….….44
Clinical Trial Protocol Amendment Form………………………………..….46
Application Form for Additional Investigators and Sites…………..…....…49
A. Foreword
The Pharmaceutical Act (No. 14) of 2004 requires that Clinical trails intended to
be conducted in Zambia meet acceptable standards of Good Clinical Practice
(GCP).
It is therefore my sincere hope that these guidelines will provide the necessary
information in preparing and submitting documents for conducting clinical trails in
Zambia.
Finally, I wish to urge our esteemed readers and applicants to read this first
edition of guidelines carefully and make as many suggestions as possible so that
we have a version of the guidelines that are commensurate with current
practices.
Dr S.M. Miti
PERMANENT SECRETARY
Ministry of Health
:
B. Acknowledgments
The Ministry of Health (MoH) and the Pharmaceutical Regulatory Authority (PRA)
wish to acknowledge the immense contributions of individuals and originations
that constituted the Technical Working Group in developing these guidelines. The
principal contributors for this guidance document were:
The MoH and PRA would further like to thank the World Health Organisation
(WHO) for providing financial and technical support to the development of these
guidelines.
Ms E. Mwape
DIRECTOR-GENERAL
Pharmaceutical Regulatory Authority
C. GLOSSARY
1.6 Audit
A systematic and independent examination of trial related activities and
documents to determine whether the evaluated trial related activities were
conducted, and the data were recorded, analyzed and accurately reported
according to the protocol, sponsor's standard operating procedures (SOPs),
Good Clinical Practice (GCP), and the applicable regulatory requirement(s).
1.10 Blinding/Masking
A procedure in which one or more parties to the trial are kept unaware of the
treatment assignment(s). Single-blinding usually refers to the subject(s) being
unaware, and double-blinding usually refers to the subject(s), investigator(s),
monitor, and, in some cases, data analyst(s) being unaware of the treatment
assignment(s).
1.17 Contract
A written, dated, and signed agreement between two or more involved parties
that sets out any arrangements on delegation and distribution of tasks and
obligations and, if appropriate, on financial matters. The protocol may serve as
the basis of a contract.
1.22 Documentation
All records, in any form (including, but not limited to, written, electronic, magnetic,
and optical records, and scans, x-rays, and electrocardiograms) that describe or
record the methods, conduct, and/or results of a trial, the factors affecting a trial,
and the actions taken.
1.29 Inspection
The act by a regulatory authority(ies) of conducting an official review of
documents, facilities, records, and any other resources that are deemed by the
authority(ies) to be related to the clinical trial and that may be located at the site
of the trial, at the sponsor's and/or contract research organization’s (CRO’s)
facilities, or at other establishments deemed appropriate by the regulatory
authority(ies).
1.34 Investigator
A physician, dentist or other qualified person who conducts a clinical trial at a trial
site. See also Sub-investigator.
1.38 Monitor
The person responsible for ensuring that the study is performed at the agreed
progression and that it is conducted, recorded, and reported in accordance with
the protocol, Standard Operating Procedures (SOPs), Good Clinical Practice
(GCP), and the applicable regulatory requirement(s).
1.44 Protocol
A document that describes the objective(s), design, methodology, statistical
considerations, and organization of a trial. The protocol usually also gives the
background and rationale for the trial, but these could be provided in other
protocol referenced documents. Throughout the ICH GCP Guideline the term
protocol refers to protocol and protocol amendments.
1.48 Randomization
The process of assigning trial subjects to treatment or control groups using an
element of chance to determine the assignments in order to reduce bias.
1.53 Sponsor
An individual, company, institution, or organization, which takes responsibility for
the initiation, management, and/or financing of a clinical trial.
1.54 Sponsor-Investigator
An individual who both initiates and conducts, alone or with others, a clinical trial,
and under whose immediate direction the investigational product is administered
to, dispensed to, or used by a subject. The term does not include any person
other than an individual (e.g., it does not include a corporation or an agency).
The obligations of a sponsor-investigator include both those of a sponsor and
those of an investigator.
2.1 An application for approval to conduct a clinical trial is required for the
following categories of medicines:
a. Unregistered medicines
b. Registered medicines where the proposed clinical trials are outside of
the conditions of approval. These may include changes to:
i. indication(s) and clinical use
ii. target patient population(s)
iii. route(s) of administration
iv. dosage regimen(s)
3.3 The applicant and all investigators must sign declarations that they are
familiar with and understand the clinical trial protocol and will comply with
Good Clinical Practice standards, as determined by the Regulatory
Authority, in the conduct of the trial.
3.4 In the case of multicentre trials, the coordinating investigator must also
sign the application form.
3.5 Upon signing the application, all parties accept responsibility that all
applicable regulations and requirements will be adhered to. Furthermore,
all parties are responsible for ensuring that the trial is based on and
implemented according to well-founded ethical and scientific principles,
which are expressed in the Helsinki Declaration and its current revisions
as well as in international guidelines for Good Clinical Practice (GCP).
3.7 All investigators in a clinical trial as well as the trial monitor must have had
formal training in Good Clinical Practice (GCP) within the last three years.
4. Ethical Assessment:
4.1 A clinical trial that has received approval from the Regulatory Authority
may only proceed once clearance has also been obtained from a
recognized Research Ethics Committee for a particular trial site.
4.2 Ethical evaluations of clinical trials of drugs must take place in accordance
with the principles of Good Clinical Practice as well as the Declaration of
Helsinki and its current revisions.
5.1 All subjects must be satisfactorily insured against possible injuries that
might arise during the conduct of the clinical trial.
5.2 For all sponsor-initiated trials, a valid insurance certificate for the duration
of the study must be provided prior to study initiation.
6.1 Applicants must be able to demonstrate that clinical trials are conducted
according to generally accepted principles of good clinical practice.
6.4 The rights, safety, and well being of the trial subjects are the most
important considerations and must prevail over interests of science and
society.
6.7 A trial must be conducted in compliance with a protocol that has received
regulatory and ethics approval prior to initiation.
6.8 The medical care given to, and medical decisions made on behalf of,
subjects must always be the responsibility of a qualified physician or,
when appropriate, of a qualified dentist.
6.10 Freely given informed consent must be obtained from every subject prior
to clinical trial participation.
6.11 All clinical trial information must be recorded, handled, and stored in a way
that enables its accurate reporting, interpretation and verification.
6.14 Systems with procedures that assure the quality of every aspect of the trial
must be implemented.
7. The Clinical Trial Application:
8.1 The clinical trial protocol must contain at least the following information,
consistent with the requirements of internationally accepted GCP
guidelines:
8.1.1 Background and purpose of the trial
8.1.2 Details of the study population;
8.1.3 Design and type of trial
8.1.4 Criteria for selection of trial subjects
8.1.5 Trial treatments
8.1.6 Control groups and control treatments where applicable
8.1.7 Choice of method and statistical justification for the number of trial
subjects
8.1.8 Monitoring, assessment and reporting of effects, adverse drug
reactions and adverse events
8.1.9 Clinical and laboratory safety tests
8.1.10 Assessment of results
8.1.11 Quality assurance of data and procedures
8.1.12 Drug accountability
8.1.13 Ethical assessment
10.1 Investigational, comparator and /or placebo products used in a clinical trial
must be properly labelled and contain the following information:
10.1.1 A statement indicating that the drug is an investigational drug to be
used only by a qualified investigator
10.1.2 The name, number or identifying mark of the drug
10.1.3 The expiration date of the drug
10.1.4 The recommended storage conditions for the drug
10.1.5 The lot number of the drug
10.1.6 The name and address of the sponsor
10.1.7 The protocol code or identification
10.1.8 The name and address of the premises where the clinical trial is to
be carried out.
10.2 Registered products that are incorporated in the trial must also be labelled
in accordance with 10.1 above.
10.3 Trial medications must be stored and dispensed by the pharmacy or the
pharmaceutical department at the trial site in accordance with good
dispensing practices. The general principle is that investigational products
used in clinical trials should be handled in the same way as registered
medicines.
11.2 Certificates of analysis (COAs) must be provided for all investigational and
comparator products.
b. Dosage Form:
Source
Developmental Pharmaceutics
Formulation and Method of Manufacture and Packaging
Specifications and Test Methods and Batch Analyses
Stability
12.2 A copy of the written information intended for trial subjects, as it will be set
out in the informed consent form, that includes a statement of the risks
and anticipated benefits arising to the health of trial subjects as a result of
their participation in the clinical trial, must be submitted to the Regulatory
Authority.
12.3 The following list of items (not exhaustive), should be included in the
patient information leaflet:
12.3.1 An introduction including information on participation in the
study
12.3.2 The aims, objectives and goals of the study
12.3.3 The methods to be employed and what this will involve for
the trial subject
12.3.4 Criteria for selection that apply to the subject
12.3.5 Whether the trial has any direct benefit for the trial subject
12.3.6 Which medicines are included in the trial; whether the
preparations are available on the market and if inactive
substances (placebo) will be used. The patient must be
informed of the fact that allocation to a specific treatment
group will occur at random
12.3.7 Other medicines that may/may not be taken at the same
time as the trial medication. Non-prescription medications
and complementary products should be mentioned
specifically
12.3.8 Pregnant and breast-feeding subjects must be excluded
from participation in the study and safe contraceptives must
be used by women of a childbearing age. Information
concerning safe use of contraceptives for men, if this is
relevant, must be provided
12.3.9 Practical consequences of participating (type of involvement,
time required)
12.3.10 Risks, adverse drug reactions and any possible discomfort
should be detailed
12.3.11 If the person does not consent to participate, details of
alternative treatments available must be provided
12.3.12 Discontinuing current treatment as a condition of
participating
12.3.13 Follow-up treatment, if applicable
12.3.14 Confidentiality
12.3.15 Emphasis that participation is voluntary and that consent can
be withdrawn at any time and without having to provide
reasons. Subjects must be informed that refusing to
participate will have no effect on further treatment or the
relationship to the treating physician or to the institute
12.3.16 Information that Regulatory Authorities and Research Ethics
Committees may require access to subject identifying data.
Consent for this access must be a condition for participation
in the study
12.3.17 Information about who the trial subject can contact. This
should include details of the investigator, Research Ethics
Committee and Regulatory Authority
12.3.18 Information about indemnity, insurance and compensation in
the event of trial-related injury
12.3.19 Information if biological fluids will be used and/or stored for
pharmacogenetic sub-studies. Participation in this part of
the study should be voluntary and a separate informed
consent must be obtained
12.4 Additionally, the following issues, where applicable, must be addressed in
the process of obtaining informed consent:
12.4.1 Trials on under-aged subjects and subjects with reduced
competence to consent
12.4.2 Withdrawal of consent
12.4.3 Provision of new information to subjects as these become
available
13.2 The applicant must submit the original wording, revised wording, and
rationale for the change including a copy of a complete protocol
incorporating all amendments.
13.4 Approval must be obtained for the following amendments to the clinical
trial protocol:
13.4.1 Changes that affect patient selection and monitoring
13.4.2 Changes that affect clinical efficacy and safety requirements
(e.g. dosage adjustments, study procedures, etc)
13.4.3 Changes that affect patient discontinuation
13.4.4 Changes that result in the extension of the duration of the
clinical trial
13.4.5 Changes that result to the chemistry and manufacturing
information that may affect drug safety and quality (For
example: specifications for the drug where the limits of the
test are relaxed or deleted; where a new impurity or
degradation product has been identified; and, the addition of
new raw materials, solvents, reagents, catalysts or any other
material used in the manufacture of the drug substance.)
14.1 The sponsor must record, handle and store all information in respect of a
clinical trial in order to ensure that the clinical trial is conducted in
accordance with good clinical practices and in a way that allows its
complete and accurate reporting as well as its interpretation and
verification.
14.2 The sponsor must keep all records related to the conduct of a clinical trial
in a format that facilitates verification for the purpose of an inspection.
14.3 The sponsor must submit requested records within 48 hours if safety
concerns arise.
14.5 The sponsor must maintain complete and accurate records in respect of
the use of a drug in a clinical trial, including:
16.1 The term adverse drug reactions is understood as adverse events where
the connection to the trial medication cannot be excluded (possible or
probable connection).
16.2 The sponsor must report serious adverse drug reactions that emerge
during trials as individual reports (one report per patient).
16.3 During the course of a clinical trial, the sponsor must inform the
Regulatory Authority and the Research Ethics Committee of any serious
unexpected adverse drug reaction in respect of the drug that has occurred
locally or internationally as follows:
16.4 The potential connection to the study drug must be clarified, and updated
reports sent to the Regulatory Authority as soon as these are available.
16.5 With regard to adverse drug reaction that are serious and already known
(described in Investigator’s Brochure or the Summary of Product
characteristics (SPC)) there are no fixed time limits. These cases must be
reported as soon as the necessary information is available.
17.1 The applicant conducting the clinical trial must submit progress reports to
the Regulatory Authority on a six monthly basis from the date of initiation
of the clinical trial and within 30 days of the completion or termination of
the clinical trial
E. APPENDICES
APPLICATION TO CONDUCT
A CLINICAL TRIAL
APPLICATION TO CONDUCT A CLINICAL TRIAL
The following are the requirements when submitting an application
to conduct a clinical trial:
i. Covering letter
ii. Cover sheet
iii. Checklist
iv. Completed Application form
v. All documents and electronic copies to be submitted in duplicate
vi. Final version of the Clinical Trial Protocol
vii. Patient Information leaflet and Informed Consent form
viii. Investigators Brochure and/or Package Insert
ix. Signed investigator(s) CV(s) in required format
x. Signed declaration by Principal investigator(s)
xi. Signed joint declaration by Sponsor/National Principal
investigator
xii. Signed declaration by Co- or Sub-investigators
xiii. Signed declaration by regional monitor and/or study coordinator
xiv. Indemnity and Insurance Certificate and/or
xv. Proof of Malpractice insurance of trialist(s)
xvi. Ethics Committee(s) approval or
xvii. Copy of letter submitted to Ethics Committee(s)
xviii. Diskettes to be submitted in Microsoft Word format
xix. Financial declaration by Sponsor and Principle investigator
CLINICAL TRIAL APPLICATION
COVER SHEET
Study Title:
Protocol No:
Study Drug:
Sponsor:
Applicant:
Contact Person:
Address:
Telephone Number: Fax Number:
Cell Number:
E-mail address:
CHECKLIST
COVERING LETTER
CERTIFICATE(S) OF ANALYSIS
INSURANCE CERTIFICATE
AND IF NECESSARY:
LETTER ENDORSING GENERIC INSURANCE CERTIFICATE
ETHICS APPROVAL
OR
COPY OF LETTER APPLYING FOR ETHICS COMMITTEE APPROVAL
National Co-coordinator /
Other (state designation)
SECTION 2 – ADMINISTRATIVE AND SUPPLEMENTARY DETAILS
Title:
Protocol Number/identification:
Date of final protocol:
2.8 Registration status of trial medication, for the indication to be tested in this
trial, in other countries:
[i.e. Country: date registered / date applied for / date registration refused /
date registration withdrawn by applicant / date registration cancelled by
regulatory authority) [Attach as an appendix if necessary]
5.1 Provide an explanation if the trial is to be conducted locally only and not in
the host country of the applicant / sponsor:
5.4 Details of other Regulatory Authorities which have approved this trial.
Include date(s) of approval and number of sites per country:
5.6 Details of and reasons for this trial having been suspended at any stage by
other Regulatory Authorities, if applicable:
5.7 Details if this trial is being undertaken in other SADC countries, any
other country in Africa, or any country where there is no regulatory
control of clinical trials:
5.8 Previous studies using this agent which have been approved by the
Regulatory Authority:
Approval number:
Study title:
Protocol number:
Date of approval:
Principal Investigator:
Date(s) of progress report(s):
Date of final report:
5.9 If any sub-studies are proposed as part of this protocol, indicate whether
these will also be conducted locally. If not, please explain:
Part 6: ETHICS
6.1 Research Ethics Committee responsible for each site, date of approval or
date of application:
6.2 State which Good Clinical Practice (GCP) guidelines are being followed:
1. Title:
2. Protocol Number/Identification:
5. Objectives of study:
[These should be clearly listed and justified]
6. Study design:
[These should be clearly described and each component justified. Include
study phase, use of placebo, dosages, randomisation, blinding, duration of
treatment, etc.]
7. Trial Participants:
[Number of participants; ability to enrol required number within stated time,
etc]
Reviewer’s recommendation:
Signature of reviewer:
Date:
Appendix 2
1. Study Title:
2. Protocol Number:
3. Designation:
[e.g. National Principal Investigator, Investigator (Principal, Co- or sub-), Study Co-
ordinator, Regional Monitor, Local Monitor, Clinical Research Associate]
4. Personal Details
Name:
Work Address:
Telephone Number:
Fax Number:
Cell-phone Number:
e-mail address:
12. Any additional relevant information supporting abilities to participate in conducting this
trial
[Briefly]
Signature: Date:
Appendix 3
Protocol:
And
Hereby declare that sufficient funds have been made available to complete the above-identified
study.
Signed Date
Signed Date
Name:
Title of Trial:
Protocol:
Site:
1. I am familiar with internationally accepted standards of Good Clinical Practice (GCP) and
understand the responsibilities and obligations of the Principle Investigator within the context
of this study.
2. I have notified the regulatory authority of any aspects of the above with which I do not / am
unable to, comply. (If applicable, this may be attached to this declaration.)
3. I have thoroughly read, understood, and critically analysed the protocol and all applicable
accompanying documentation, including the investigator’s brochure, patient information
leaflet(s) and informed consent form(s).
4. I will conduct the trial as specified in the protocol and in accordance with Good Clinical
Practice (GCP).
5. To the best of my knowledge, I have the potential at the site(s) I am responsible for, to recruit
the required number of suitable participants within the stipulated time period.
6. I will not commence with the trial before written authorisations from the relevant Research
Ethics Committee(s) as well as the Regulatory Authority have been obtained.
7. I will obtain informed consent from all participants or if they are not legally competent, from
their legal representatives.
8. I will ensure that every participant (or other involved persons), shall at all times be treated in a
dignified manner and with respect.
9. Using the broad definition of conflict of interest below, I declare that I have no financial or
personal relationship(s) which may inappropriately influence me in carrying out this clinical
trial.
[Conflict of interest exists when an investigator (or the investigator’s institution), has financial
or personal associations with other persons or organizations that may inappropriately
influence (bias) his or her actions.]*
*Modified from: Davidoff F, et al. Sponsorship, Authorship, and Accountability. (Editorial)
JAMA Volume 286 number 10 (September 12, 2001)
10. I have* / have not (delete as applicable) previously been the principal investigator at a site
which has been closed due to failure to comply with Good Clinical Practice. (*Attach details.)
11. I have* / have not (delete as applicable) previously been involved in a trial which has been
closed as a result of unethical practices. (*Attach details)
12. I will submit all required reports within the stipulated time-frames.
Signature: Date:
Witness: Date:
Appendix 5
Title of Trial:
Protocol:
Site:
Designation:
13. I am familiar with internationally accepted standards of Good Clinical Practice (GCP) and
understand the responsibilities and obligations of the Investigator within the context of this
study.
14. I will carry out my role in the trial as specified in the protocol and in accordance with Good
Clinical Practice (GCP).
15. I will not commence with my role in the trial before written authorisations from the relevant
Research Ethics Committee(s) as well as the Regulatory Authority have been obtained.
16. If applicable to my role in the trial, I will ensure that informed consent has been obtained from
all participants or if they are not legally competent, from their legal representatives.
17. I will ensure that every participant (or other involved persons, such as relatives) shall at all
times be treated in a dignified manner and with respect.
18. Using the broad definition of conflict of interest below, I declare that I have no financial or
personal relationship(s) which may inappropriately influence me in carrying out this clinical
trial.
[Conflict of interest exists when an investigator (or the investigator’s institution), has financial
or personal relationships with other persons or organizations that inappropriately influence
(bias) his or her actions.]*
*Modified from: Davidoff F, et al. Sponsorship, Authorship, and Accountability. (Editorial)
JAMA Volume 286 number 10 (September 12, 2001)
19. I have not previously been involved in a trial which has been closed due to failure to comply
with Good Clinical Practice.
20. I will submit all required reports within the stipulated time-frames.
Signature: Date:
Witness: Date:
Appendix 6
Name:
Title of Trial:
Protocol:
Site:
21. I am familiar with internationally accepted standards of Good Clinical Practice (GCP) and
understand the responsibilities and obligations of the clinical trial Monitor within the context of
this study.
22. I have notified the regulatory authority of any aspects of the above with which I do not / am
unable to, comply. (If applicable, this may be attached to this declaration.)
23. I will carry out my responsibilities as specified in the trial protocol and accordance with Good
Clinical Practice (GCP)
24. Using the broad definition of conflict of interest below, I declare that I have no financial or
personal relationship(s) which may inappropriately influence me in carrying out this clinical
trial.
[Conflict of interest exists when an investigator (or the investigator’s institution), has financial
or personal relationships with other persons or organizations that inappropriately influence
(bias) his or her actions.]*
*Modified from: Davidoff F, et al. Sponsorship, Authorship, and Accountability. (Editorial)
JAMA Volume 286 number 10 (September 12, 2001)
25. I have* / have not (delete as applicable) previously been the monitor at a site which has been
closed due to failure to comply with Good Clinical Practice. (*Attach details.)
26. I have* / have not (delete as applicable) previously been involved in a trial which has been
closed as a result of unethical practices. (*Attach details)
27. I will submit all required reports within the stipulated time-frames.
Signature: Date:
Witness: Date:
APPENDIX 7
PROTOCOL AMENDMENT
INCREASE IN NUMBER OF PATIENTS PARTICIPATING
CHANGES IN DOSE / REGIMENT OF STUDY DRUG
STUDY TITLE:
PROTOCOL NUMBER:
DATE:
1. APPLICANT
3. AMENDMENT PARTICULARS
(Please list requests for approval)
Does the applicant wish to increase the number of local subjects participating in
this trial?
Yes
No
Does the applicant wish to change the dose / regimen of the study drug?
Yes
No
Does this amendment request require a new consent form to be signed by the
participant?
Yes
No
If “Yes” please submit new PIL together with this application.
3.2 Version Number and Date of Protocol Amendment (for each document
submitted):
3.3 General motivation for the proposed Amendment: [List all of the issues
included in the amendment and provide the rationale for each
amendment]
If NO: Specify the investigator(s) / site(s) for which the Amendment will apply:
STUDY TITLE:
PROTOCOL NUMBER:
DATE:
1. APPLICANT
3. INVESTIGATOR DETAILS
4.1 Describe how the site is structured so as to be able to take on the work
for which this application is being made: [Give details of support staff,
facilities, back up and any other relevant infrastructure]
5.1 Briefly explain the reason for the new investigator/s or site(s):
______
Applicant (local contact) Date